Macquarie Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-60,000
| Closed | -$3.52M | – | 1966 |
|
|
2023
Q4 | $3.52M | Hold |
60,000
| – | – | ﹤0.01% | 1059 |
|
|
2023
Q3 | $2.61M | Hold |
60,000
| – | – | ﹤0.01% | 1089 |
|
|
2023
Q2 | $2.17M | Hold |
60,000
| – | – | ﹤0.01% | 1164 |
|
|
2023
Q1 | $2.23M | Hold |
60,000
| – | – | ﹤0.01% | 1129 |
|
|
2022
Q4 | $2.72M | Sell |
60,000
-638
| -1% | -$41.3K | ﹤0.01% | 1115 |
|
|
2022
Q3 | $4.26M | Sell |
60,638
-417
| -0.7% | -$30.9K | 0.01% | 1031 |
|
|
2022
Q2 | $4.1M | Sell |
61,055
-9,043
| -13% | -$575K | ﹤0.01% | 1086 |
|
|
2022
Q1 | $5.76K | Buy |
70,098
+288
| +0.4% | +$29.5K | ﹤0.01% | 1078 |
|
|
2021
Q4 | $10.2M | Buy |
69,810
+212
| +0.3% | +$32.9K | 0.01% | 928 |
|
|
2021
Q3 | $12.3M | Sell |
69,598
-2,725
| -4% | -$438K | 0.01% | 872 |
|
|
2021
Q2 | $11.7M | Sell |
72,323
-9,451
| -12% | -$1.52M | 0.01% | 899 |
|
|
2021
Q1 | $14M | Sell |
81,774
-12,234
| -13% | -$2.42M | 0.02% | 633 |
|
|
2020
Q4 | $20.6M | Sell |
94,008
-25,787
| -22% | -$5.57M | 0.03% | 507 |
|
|
2020
Q3 | $19.9M | Sell |
119,795
-65,376
| -35% | -$8.95M | 0.03% | 470 |
|
|
2020
Q2 | $21.1M | Buy |
185,171
+6,900
| +4% | +$669K | 0.04% | 452 |
|
|
2020
Q1 | $13.7M | Hold |
178,271
| – | – | 0.03% | 496 |
|
|
2019
Q4 | $23M | Sell |
178,271
-57,659
| -24% | -$5.56M | 0.03% | 479 |
|
|
2019
Q3 | $18.4M | Buy |
235,930
+12,300
| +6% | +$1.15M | 0.03% | 467 |
|
|
2019
Q2 | $23M | Hold |
223,630
| – | – | 0.04% | 429 |
|
|
2019
Q1 | $16.4M | Hold |
223,630
| – | – | 0.03% | 516 |
|
|
2018
Q4 | $9.49M | Hold |
223,630
| – | – | 0.02% | 606 |
|
|
2018
Q3 | $10.5M | Sell |
223,630
-1,500
| -0.7% | -$83.5K | 0.02% | 636 |
|
|
2018
Q2 | $11.1M | Buy |
225,130
+1,500
| +0.7% | +$56.7K | 0.02% | 612 |
|
|
2018
Q1 | $6.87M | Buy |
223,630
+143,030
| +177% | +$3.97M | 0.01% | 692 |
|
|
2017
Q4 | $1.47M | Buy |
80,600
+600
| +0.8% | +$9.31K | ﹤0.01% | 1117 |
|
|
2017
Q3 | $936K | Hold |
80,000
| – | – | ﹤0.01% | 1232 |
|
|
2017
Q2 | $292K | Hold |
80,000
| – | – | ﹤0.01% | 1376 |
|
|
2017
Q1 | $416K | Hold |
80,000
| – | – | ﹤0.01% | 1348 |
|
|
2016
Q4 | $380K | Hold |
80,000
| – | – | ﹤0.01% | 1369 |
|
|
2016
Q3 | $529K | Sell |
80,000
-80,000
| -50% | -$426K | ﹤0.01% | 1281 |
|
|
2016
Q2 | $874K | Buy |
+160,000
| New | +$2.55M | ﹤0.01% | 1304 |
|
Other funds holding MRTX
Macquarie Group's MRTX Position: Q1 2024 in Review
Macquarie Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 60,000 shares — an estimated $3.52M sold.
Macquarie Group first reported a position in MRTX in Q2 2016 and held it in 31 quarters. The position peaked at $23M in Q2 2019. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Macquarie Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Macquarie Group sold 60,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.52M.
- Macquarie Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2016 and held it in 31 quarters.
- Macquarie Group's Mirati Therapeutics, Inc. Common Stock position peaked at $23M in Q2 2019.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Macquarie Group's 13F filing for Q1 2024, filed 14 May 2024.